1Berg PA, Klein R. Anti-mitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis 1992; 10:85-101.
2Bunn CC, McMorrow M. Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anti-centromere and anti-M2 antibodies. Clin Exp Immunol 1995;102:131-136.
3Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002; 97:999-1002.
4Heathcote EJ. Management of Primary Biliary Cirrhosis.Hepatology 2000; 31:1005-1013.
5Dickson ER, Grambsch PM, Fleming TR, Fisher LD,Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
6Sakugawa H, Nakasone H, Nakayoshi T, Yamashiro T,Maeshiro T, Kobashigawa K, Kinjo F, Saito A, Zukeran H,Nakanuma Y, Ohba K. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa, Japan. Hepatol Res 2003;26:330-336.
7Flisiak R, Wiercinska-Drapalo A, Prokopowicz D. Antibodies against M2 antigen in differential diagnosis of primary biliary cirrhosis. Pol Merk Lek 2000; 8:373-375.
8Reisman Y, van Dam GM, Gips CH, Lavelle SM, Euricterus PM. Survival probabilities of Pugh-Child-PBC classified patients in the euricterus primary biliary cirrhosis population,based on the Mayo clinic prognostic model. Euricterus Project Management Group. Hepatogastroenterology 1997; 44: 982-989.
9Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years. Gastroenterology 2002; 123:1044-1051.
10Krzeski P, Zych W, Kraszewska E, Milewski B, Butruk E,Habior A. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 1999;30:865-869.
